Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil

Keiichi Taniguchi1,2, Yoshinori Ando1, Haruaki Nobori1,3, Shinsuke Toba1,3, Takeshi Noshi1, Masanori Kobayashi1,5, Makoto Kawai1, Ryu Yoshida1, Akihiko Sato1,3, Takao Shishido1, Akira Naito3, Keita Matsuno1,4, Masatoshi Okamatsu2, Yoshihiro Sakoda2,4 & Hiroshi Kida3,4

Human infections with avian-origin influenza A(H7N9) virus represent a serious threat to global health; however, treatment options are limited. Here, we show the inhibitory effects of baloxavir acid (BXA) and its prodrug baloxavir marboxil (BXM), a first-in-class cap-dependent endonuclease inhibitor, against A(H7N9), in vitro and in vivo. In cell culture, BXA at four nanomolar concentration achieved a 1.5–2.8 log reduction in virus titers of A(H7N9), including the NA-R292K mutant virus and highly pathogenic avian influenza viruses, whereas NA inhibitors or favipiravir required approximately 20-fold or higher concentrations to achieve the same levels of reduction. A(H7N9)-specific amino acid polymorphism at position 37, implicated in BXA binding to the PA endonuclease domain, did not impact on BXA susceptibility. In mice, oral administration of BXM at 5 and 50 mg/kg twice a day for 5 days completely protected from a lethal A/Anhui/1/2013 (H7N9) challenge, and reduced virus titers more than 2–3 log in the lungs. Furthermore, the potent therapeutic effects of BXM in mice were still observed when a higher virus dose was administered or treatment was delayed up to 48 hours post infection. These findings support further investigation of BXM for A(H7N9) treatment in humans.

Influenza pandemics arise when novel reassortant influenza A viruses acquire zoonotic potential and adapt to enable efficient and widespread human-to-human infection1. The avian influenza A(H7N9) virus is an urgent concern for global public health due to the potential for pandemic spread1. In March 2013, the first outbreak in humans with an Asian lineage A(H7N9) were reported in China3. A(H7N9) was initially characterized as a low pathogenic avian influenza virus which caused mild disease in avian hosts1, however, of particular concern, were the acquisition of certain mutations (Leu226 in HA and Glu627 in PB2) which facilitated a switch to human-type receptor specificity enabling replication at temperatures present in the human respiratory tract5–7. Since early 2013, influenza A(H7N9) viruses have caused five distinct epidemic waves8, and laboratory-confirmed human cases admitted to hospital with A(H7N9) exhibited high case fatality rates9. The highest number of human cases with A(H7N9) occurred in China from October 2016 and the number of cases exceeded those reported in the previous waves10,11. Importantly, highly pathogenic A(H7N9) viruses were isolated from humans during the fifth epidemic wave10. As of October 2018, a total of 1,567 laboratory-confirmed human cases (with 615 deaths) of A(H7N9) infections in humans have been reported12.

Antiviral medications are of critical importance to reduce the burden of disease caused by A(H7N9) and the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of antivirals for treatment of all hospitalized cases of human infection with novel influenza A viruses associated with severe disease13. While the A(H7N9) viruses are resistant to M2-ion channel blockers, treatment with oseltamivir and peramivir have been
The influenza RNA polymerase complex, composed of the PA, PB1 and PB2 subunits, helps mediate a unique “cap-snatching” mechanism and thereby plays a crucial role during both the replication and transcription stages of the viral life cycle. As a result the cap-snatching mechanism is considered a promising antiviral target. The cap-dependent endonuclease (CEN) in the PA subunit cleaves bound-capped RNAs 10–13 nucleotides from the 5′ ends of nascent transcripts to generate a primer for the synthesis of viral mRNA. The active center of CEN is also highly conserved across seasonal, pandemic, and highly pathogenic avian influenza viruses, indicating that CEN inhibitors have the potential to be broadly-active anti-influenza drugs.

Baloxavir marboxil (BXM), which is converted metabolically to its active form baloxavir acid (BXA), is an orally available CEN inhibitor that has recently been approved for clinical use (single dose of 40 mg for patients 40 kg to < 80 kg or 80 mg for patients ≥ 80 kg) in adults and adolescents in Japan and the United States. To enhance oral absorption of BXA, the phenolic hydroxyl group was modified, yielding the prodrug BXM. Notably, BXA exhibits broad antiviral activities against several subtypes of influenza A and B viruses in vitro, and co-crystal structures of PA endonuclease domain from influenza A and B viruses support broad spectrum activity for this class of compounds. Therefore, BXM is anticipated to be an additional and alternative option for treatment of avian-origin influenza A viruses; however, information on the in vivo potency of BXA and in vivo efficacy of BXM is still limited. In the present study, we report the antiviral activities of BXA and BXM against human influenza A(H7N9) viruses, including highly pathogenic avian influenza viruses. Our findings support further investigation of the therapeutic efficacy of BXM treatment in A(H7N9)-infected patients.

**Results**

**Inhibitory effect of BXA on A(H7N9) virus replication in vitro.** Avian-origin influenza A(H7N9) viruses typically harbor a polymorphic alanine to serine substitution at residue 37 in the PA (A37S)^16,17, which is involved in BXA binding in the endonuclease domain (Table 1)^26,29. To examine whether BXA possessed inhibitory activity against human A(H7N9) virus in vitro, we selected strains from subtypes A(H7N9) and A (H7N3), including highly pathogenic avian influenza viruses, isolated from 2013 to 2018 harboring alanine or serine at residue 37 in the PA. To compare the degree of inhibition of virus replication by approved drugs, a yield reduction assay using Madin-Darby canine kidney (MDCK) cells was employed. The mean concentration achieving 90% (1-log) reduction in virus titer (EC90) values of approved drugs and virus titers under different drug concentrations are shown in Table 1. Amino acid polymorphisms of the BXA binding domain in PA from human and avian influenza A viruses. The indicated amino acids have been previously shown to be involved in BXA binding to the active center of the endonuclease domain in the PA subunit (residues 20, 24, 34, 37, 38, 41, 80, 108, 119, 130, and 134) and associated with reduced susceptibility to BXA (residues 23, 37, 38 and 199) as reported previously. The amino acids different from the consensus sequence of human influenza A viruses are highlighted in boldface and underlined. Highly pathogenic avian influenza viruses. The consensus sequences were determined by alignment analysis with the full-length PA sequences obtained from the National Center for Biotechnology Information (NCBI) and Global Initiative on Sharing All Influenza Data (GISAID) on October 24, 2018. Each number shown in parentheses represents frequency (%) of the most frequent variants among 1,094, 10,312, 13,185 and 196 of PA sequences from H7N9, H1N1, H3N2 and H5N1, respectively.

Table 1. Amino acid polymorphisms of the BXA binding domain in PA from human and avian influenza A viruses. The indicated amino acids have been previously shown to be involved in BXA binding to the active center of the endonuclease domain in the PA subunit (residues 20, 24, 34, 37, 38, 41, 80, 108, 119, 130, and 134) and associated with reduced susceptibility to BXA (residues 23, 37, 38 and 199) as reported previously. The amino acids different from the consensus sequence of human influenza A viruses are highlighted in boldface and underlined.

![Table 1](image-url)
was comparable to that of the vehicle-treated group, whereas OSP treatment at 50 mg/kg twice a day for 5 days showed improvements in survival in mice infected with A/Anhui/1/2013 (H7N9).

To further investigate the anti-viral activity of BXM, we used a lung virus yield reduction assay in MDCK cells. BXM exerted significantly suppressed body weight loss. By contrast, BXM significantly prevented body weight loss from day 2 to 5 in a dose-dependent manner, when compared to vehicle and OSP. These results indicate that BXM exerts a profound inhibitory effect on both proinflammatory cytokine and chemokine production in the lungs of mice infected with A(H7N9).

Table 2 and Supplementary Table 1, respectively. BXA showed inhibitory activity against A/Anhui/1/2013 (H7N9) strain as previously reported^18^ and exhibited comparable potency against A/Anhui/1/2013 (H7N9) harboring the NA-R292K substitution to the wild-type, indicating no cross-resistance with NAIs was observed. BXA also exhibited comparable potency against H7 low and highly pathogenic avian influenza viruses to A/Anhui/1/2013 (H7N9) strain. Notably, BXA at four nanomolar concentration achieved a 1.5–2.8 log reduction in viral titers (Supplementary Table 1). By contrast, NAIs or the RNA-dependent RNA polymerase inhibitor favipiravir required approximately 20-fold or higher concentrations to achieve the same levels of virus reduction as BXA. These results suggest that BXA has high antiviral activity against A(H7N9) despite the viruses possessing the polymorphic PA-A37S substitution located in the adjacent BXA-binding site. In addition, BXA exhibits a 20-fold greater degree of inhibition of virus replication compared to the other approved drugs in vitro.

**Protective efficacy of BXM on lethal infections of A(H7N9) in vivo.** In order to evaluate the effects of BXM against A(H7N9) in a lethal infection model, mice were inoculated with 10.4 times of 50% mouse lethal dose (MLD_{50}) of A/Anhui/1/2013 (H7N9). All vehicle-treated mice died within 7 days post-infection (dpi) and mean day to death was 6 days (Fig. 1a). Clinically-equivalent dosing of oseltamivir phosphate (OSP), 5 mg/kg twice a day for 5 days, and a supratherapeutic dose, 50 mg/kg twice a day for 5 days, resulted in 30% and 50% survival, respectively. In this setting, survival rates of BXM at 0.5, 5, and 50 mg/kg twice a day for 1 day were 90%, 100% and 100%, respectively. When compared to survival time at 28 dpi, all groups treated with BXM showed significant prolonged survival times compared with the groups administered with vehicle or OSP. Dramatic body weight loss after infection was observed in the vehicle-treated control group and reached a 28% decrease at 5 dpi (Fig. 1b and Supplementary Fig. 2). When treated with OSP at 5 mg/kg twice a day for 5 days, body weight change was comparable to that of the vehicle-treated group, whereas OSP treatment at 50 mg/kg twice a day for 5 days significantly suppressed body weight loss. By contrast, BXM significantly prevented body weight loss from day 2 to 5 in a dose-dependent manner, when compared to vehicle and OSP. These results indicate that BXM exerts improvements in survival in mice infected with A/Anhui/1/2013 (H7N9).

**Effects of BXM on virus titers in mice infected with A(H7N9).** In order to examine the inhibitory effects of BXM on the viral replication of A/Anhui/1/2013 (H7N9) in vivo, virus titers in lung homogenates derived from infected mice were measured at 1, 3, and 5 dpi. BXM treatment at 5 and 50 mg/kg twice a day decreased virus titers in the lungs of mice by more than 3-logs compared to that of vehicle- or OSP-treatment group, while virus titers of all OSP-treated groups were comparable to those of vehicle-treated group at 1 dpi (Fig. 2). Although gradual increases of virus titers for 1-day dosing of BXM group were observed after withdrawal of treatment, virus titers were suppressed by more than 2 or 3-logs following repeated BXM treatment at 5 and 50 mg/kg compared to that of vehicle- or OSP-treatment groups. Additionally, mutation analysis of the PA N-terminal domain (residues 1 to 209) of A/Anhui/1/2013 (H7N9) was performed on lung homogenates of the infected mice treated with BXM^46^. We found no amino acid changes in the analyzed regions including residues implicated in BXA resistance by affecting BXA binding to the active center of the endonuclease domain, such as isoleucine at position 38 in the PA (Ile38)25^25^,27. These results suggest that BXM has profound inhibitory effects on viral replication in the lungs of mice infected with A(H7N9).

**Prevention of proinflammatory cytokines and chemokines production in the lungs of mice following BXM treatment.** It has been previously reported that production of proinflammatory cytokines and chemokines, such as interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, and interferon (IFN)-γ, is markedly elevated in A(H7N9)-infected patients^30^–^32^. Furthermore, A(H7N9) infection-associated inflammation in the lungs resulted in a rapidly progressive pneumonia and development of acute respiratory distress syndrome in the majority of hospitalized patients^33,34^,34. Therefore, the impact of BXM treatment upon proinflammatory cytokines and chemokines production in the lung of mice inoculated with A/Anhui/1/2013 (H7N9) was evaluated. Treatment of the A(H7N9)-infected mice with BXM at 5 and 50 mg/kg twice a day for 1 and 5 days resulted in a significantly less pronounced production of both proinflammatory cytokines and chemokines when compared with vehicle-received mice, consistent with the reduction of virus titers in the lungs of mice (Fig. 3). In contrast, OSP treatment showed a limited inhibitory effect on proinflammatory cytokines and chemokines production in the lungs of mice, and increased MIP-1α and IFN-γ production at 5 dpi. These results demonstrate that BXM has a profound inhibitory effect on both proinflammatory cytokine and chemokine production in the lungs of A(H7N9)-infected mice.

**Table 2.** Antiviral activities of BXA and reference compounds against human and avian A(H7N9) viruses in a yield reduction assay in MDCK cells. *Virus generated by reverse genetics. **Highly pathogenic avian influenza virus. *Not tested. Data represent mean ± standard deviation from three independent experiments in MDCK cells.
Protective effect of BXM on lethality in mice infected with high doses of A(H7N9).

It has been described that the pathogenicity caused by A(H7N9) challenge in mice increased in a dose-dependent manner, and therefore we next investigated the protective effect of BXM in a high-dose challenge model of A(H7N9) infection. Mice were inoculated with 3.11 MLD50 of A/Anhui/1/2013 (H7N9) and were then treated with OSP or BXM beginning immediately after virus inoculation. The mice administered with OSP at 5 and 50 mg/kg twice a day for 5 days died within 6 and 8 dpi, respectively, and no significant difference was observed on survival time up to 21 dpi compared to vehicle-treated group (Fig. 4a). Strikingly, even in these high dose challenge experimental conditions, BXM treatment at 5 and 50 mg/kg twice a day completely prevented mortality in all tested groups. BXM also significantly reduced the body weight loss in all the tested groups, whereas OSP treatment did not impact on body weight changes (Fig. 4b). Moreover, following 5-day dosing of BXM, body weight loss was within 5% throughout 28 days (Supplementary Fig. 3). In addition, BXM also significantly reduced virus titers in the lungs of mice, whereas OSP treatment had limited effect (Fig. 4c), consistent with the prior results from the 10.4 MLD50 infection model (Fig. 2). Overall, these results confirmed that BXM drastically reduces virus titers in the lungs of mice infected with A/Anhui/1/2013 (H7N9) at a high dose, resulting in greater efficacy than NAIs against lethal infection of A(H7N9) in vivo.

Delayed treatment of BXM on lethal A(H7N9) infection. To further investigate the therapeutic effect of BXM, mice infected with 10.4 times of MLD50 of A/Anhui/1/2013 (H7N9) were treated with BXM starting after 24 and 48 hours after infection, and subsequently survival and body weight loss was monitored. Mice without treatment died 5 to 7 days after infection, consistent with findings presented in Fig. 1. In this experimental condition, the 24 hours delayed treatment of BXM at 5 and 50 mg/kg twice a day for 5 days resulted in complete protection against lethal infection with A/Anhui/1/2013 (H7N9) virus (Fig. 5). The therapeutic effect was still observed with the mice given BXM at 48 hours after infection. A time-dependent protective effect by means of
body weight change was confirmed on all BXM-treated mice. These results suggest that BXM exhibits therapeutic effects against A/Anhui/1/2013 (H7N9) in mice when BXM treatment is delayed up to 48 hours after infection.

Discussion
In this study, we evaluated the in vitro antiviral activity of BXA against influenza A(H7N9) viruses, including highly pathogenic avian influenza viruses, and the therapeutic effect of BXM in vivo in murine lethal models employing influenza A(H7N9) virus. In the yield reduction assays in vitro, BXA showed superior potency against replication of A/Anhui/1/2013 (H7N9) and recent isolates of highly pathogenic avian H7 viruses compared to the approved drugs. Given that the A/duck/Japan/AQ-HE28-3/2016 (H7N9) and A/duck/Japan/AQ-HE29-22/2017 (H7N9) strains based on PA gene segments are closely related phylogenetically to human A(H7N9) isolated in the fifth wave (Supplementary Fig. 1)45, BXA should exhibit inhibitory effect against clinical isolates of highly pathogenic A(H7N9). Furthermore, BXM protected from lethal infection and exhibited significant decreases in both virus replication and proinflammatory responses in mice infected with A/Anhui/1/2013 (H7N9). Further investigations, to study the inhibitory activity of BXA against recent isolates of A(H7N9), are warranted to examine further the utility of BXM.

Although NAI-treatment for A(H7N9) infection is effective and recommended, it was reported that NAI-resistant variants (e.g. NA-R292K) were isolated from human cases24,25,46 or NAI-resistant viruses have emerged during treatment47,48. In this study, A/Anhui/1/2013 (H7N9) bearing the R292K substitution in the NA protein conferred resistance to oseltamivir acid (Table 2), whereas the mutation does not impact upon BXA susceptibility, confirming that no cross-resistance relationship exists between NAI and BXA. On the other hand, it has been reported that BXM treatment occasionally induced emergence of viruses with reduced susceptibility to BXA, that harbor the glutamic acid to lysine or glycine at position 23, the alanine to threonine at position 37, the isoleucine to threonine, phenylalanine or methionine at position 38 and the glutamic acid to glycine at position 199 substitutions in PA protein33,35. Therefore, we carefully monitored emergence of the variant viruses throughout the experiments, but no substitutions in the PA N-terminal region (residues 1 to 209) were detected following BXM treatment in mice infected with A(H7N9). Given that A(H7N9) harbors the polymorphic A37S substitution adjacent to Ile38, there is a hypothetical possibility that A37S effects on the frequency of the detection of Ile38 substitutions. Hence, it would be worth undertaking resistance isolation experiments with A(H7N9) virus and analyzing the genetic compatibility of the viruses bearing both A37S and I38T substitutions.

The therapeutic effect of oral BXM administration was investigated following A(H7N9) challenge in a lethal infection murine model. In a previous report, 5 days dosing of OSP had limited effect on the inhibition of body weight loss and the concomitant reduction of virus titers in mice infected with A/Anhui/1/2013 (H7N9) strain5. Comparable results were obtained in this study. In our model, we showed that only 1-day dosing of BXM at 0.5 mg/kg twice a day were sufficient for significant reduction of virus titers in the lungs of mice. Furthermore, 5 or 50 mg/kg twice a day dosing of BXM achieved dramatic reductions in virus titers compared to the vehicle and OSP-treated groups and resulted in significant improvements in survival. Five-day dosing of BXM at 5 or 50 mg/kg twice a day also achieved dramatic reductions in virus titers and extended the treatment
window, which indicated that repeating dose of BXM might be a reasonable option in severe cases of A(H7N9) infection. It has been suggested that the target plasma BXA concentration 24 h after a single-dose (C_{24}) be set at 6.85 ng/mL in non-clinical and clinical studies. The plasma concentration of BXA could be maintained above the target concentration of 6.85 ng/mL for at least 5 days following oral administration of BXM at 40 mg in humans. Although it is difficult to set a clinically equivalent dose regimen in mice owing to the crucial difference in half-life of BXA in plasma after oral BXM administration between humans (85.9 hours at 40 mg BXM) and mice (2.24 to 3.14 hours at 0.5 to 50 mg/kg BXM), the C_{24} of BXA after 1-day dosing of BXM at 50 mg/kg twice a day, as well as C_{120} of BXA after 5-day dosing of BXM at 5 mg/kg twice a day in mice are expected to be lower than or close to those in humans. Therefore, the dosages used in the mouse model of BXM at 50 mg/kg twice a day for 1 day or at 5 mg/kg twice a day for 5 days are comparable to the clinical dosages. On the other hand, a C_{120} of BXA after 5-day dosing of BXM at 50 mg/kg twice a day may be higher than that in humans. The existing evidence strongly suggests that BXM is has superior protective efficacy against A(H7N9) infection in murine models when compared to OSP, although further pharmacokinetic and pharmacodynamic analyses in mice and humans are required for a more complete understanding of these increased therapeutic effects exerted by BXM.

Tsang and co-workers reported that patients with high viral load correlated with the severity of influenza symptoms. It has been shown that the potency of oseltamivir acid was diminished at higher multiplicities of infection (MOI) in MDCK cells in an MOI-dependent manner, and OSP exhibited lower efficacy against higher infectious doses in a ferret model of influenza A(H5N1) virus infection. Consistent with these observations, we confirmed that OSP did not reduce either morbidity or mortality in mice infected with high infectious doses of A(H7N9). We can infer from these findings that the therapeutic efficacy of OSP against influenza

Figure 3. Suppressive effects of BXM on proinflammatory cytokine and chemokine production in the lungs of mice infected with a low dose of the A(H7N9) virus. Mice were intranasally infected with 4.0 × 10^5 TCID_{50} mouse (10.4 MLD_{50}) of A/Anhui/1/2013 (H7N9) virus, and treatment was started immediately after virus inoculation (n = 5/group). The proinflammatory cytokines and chemokines, IL-6, MCP-1, MIP-1α and IFN-γ, in the lungs at 1, 3 and 5 dpi were quantified. Dunnett’s multiple-comparison method was employed for the comparison (*p < 0.05, **p < 0.01, ***p < 0.001 compared to vehicle).
A virus infection attenuates dependent on the infectious dose. It is therefore particularly noteworthy that we demonstrated that 1-day dosing of BXM at 5 or 50 mg/kg twice a day showed greater efficacy against high dose A(H7N9) infection when compared to NAI OSP. Notably, favipiravir, which targets the viral RNA-dependent RNA polymerase, also exerted a strong effect upon the reduction of virus titers in the lungs of mice infected with high titers A(H7N9) when compared to NAIs. These results suggest that inhibition of the viral RNA polymerase machinery, particularly the “cap-snatching” mechanism, may have the potential to be more effective for reducing virus titers and provide improved benefits for the treatment of severe influenza infections with high viral burdens.

In human infection with A(H7N9), virus-induced proinflammatory cytokine and chemokine dysregulation in the lungs or serum contributes to disease severity. In addition, high levels of proinflammatory cytokines/chemokines were produced in the lungs of mice and cynomolgus macaques infected with A(H7N9) clinical isolates that replicated efficiently in the lungs. In a murine model, suppression of proinflammatory cytokine/chemokine production positively correlated with both a reduction of virus titers in lungs and the disease severity. Proinflammatory cytokines and chemokines are highly induced in the early phase of influenza virus infection, and their dysregulation is crucial for disease progression. Therefore, targeting these pathways could be a promising strategy for antiviral therapy against A(H7N9) infection.
infection and are associated with airway inflammation\textsuperscript{56,59}; thus, BXM may serve to ameliorate severe influenza pneumonia due to exerting an inhibitory effect upon the production of IL-6, MCP-1 and MIP-1α in the early stages of virus infection. Here we have shown that IFN-γ production in the lungs was also suppressed by treatment with BXM. IFN-γ production in macrophages during influenza virus infection is thought to be critically important in sustaining the cytokine/chemokine storm, and IFN-γ acts to upregulate CXCL10 transcription in airway epithelial cells, which result in infiltration of effector T cells to the lung airways\textsuperscript{60,61}. Reduction of IFN-γ thus likely limits cytokine overproduction in the lungs. These results suggest that BXM prevented virus replication followed by a concomitant decrease in the production of proinflammatory cytokines and chemokines. Thus, inhibition of virus replication in the early stages of infection appears therefore to be critically important for the amelioration of host dysfunction which likely serves to mediate the therapeutic effects.

In conclusion, this study demonstrates the high potency of BXA and BXM against influenza A(H7N9) viruses \textit{in vitro} and \textit{in vivo} compared to other currently approved antivirals. Although further investigations are required to clarify therapeutic effects against highly pathogenic avian-origin influenza A viruses \textit{in vivo}, the existing evidence supports and warrants the consideration of BXM as an alternative therapeutic option for the treatment of A(H7N9) infection in humans.

**Figure 5.** Effects of delayed treatment of BXM on a low dose of A(H7N9) infection. Mice were intranasally inoculated with $4.0 \times 10^5$ TCID$_{50}$/mouse (10.4 MLD$_{50}$) of A/Anhui/1/2013 (H7N9) viruses, and BXM treatment was started at (a) immediately, (b) 24 or (c) 48 hours after virus inoculation (n = 5/group). Vehicle or OSP treatment was started immediately after virus inoculation (n = 5/group). Survival time and body weight loss were monitored through a 21-day period after the infection. The shaded area represents the treatment period. The log-rank test was applied for comparison of the survival time between each group (*\(p < 0.01\) compared to vehicle, †\(p < 0.01\) compared to OSP at 5 mg/kg twice a day).
Methods

Compounds. Baloxavir marboxil (BXM) and baloxavir acid (BXA) were synthesized at Shionogi & Co., Ltd. Oseltamivir acid, laninamivir were purchased from Toronto Research Chemicals Inc. (Toronto, Ontario, Canada). Oseltamivir phosphate and zanamivir hydrate were obtained from Sequoia Research Products Ltd. (Pangbourne, UK). Favipiravir was supplied by PharmaBlock Sciences, Inc. (Nanjing, China).

Cells and viruses. The Madin-Darby canine kidney (MDCK; European Collection of Cell Cultures) cells were maintained at 37°C under 5% CO₂ in minimum essential medium (MEM; Nissui Pharmaceutical) supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L L-glutamine, 50 units/mL penicillin, 50 µg/mL streptomycin and 0.05% sodium hydrogen carbonate. The non-mouse adapted influenza A/Anhui/1/2013 (H7N9) virus, which is a clinical isolate and is pathogenic in mice, A/duck/Japan/AQ-HE28-3/2016 (H7N9), A/duck/Japan/AQ-HE29-22/2017 (H7N9) and A/duck/Japan/AQ-HE30-1/2018 (H7N3) were propagated in embryonated chicken eggs and harvested from virus-containing allantoic fluids. A/Anhui/1/2013 (H7N9) and A/duck/Japan/AQ-HE28-3/2016 (H7N9) possess low pathogenicity, A/duck/Japan/AQ-HE29-22/2017 (H7N9) and A/duck/Japan/AQ-HE30-1/2018 (H7N3) possess high pathogenicity. Recombinant A/Anhui/1/2013 (H7N9) virus harboring NA-R292K was generated by plasmid-based reverse genetics. Recombinant virus was propagated in embryonated chicken eggs and harvested from virus-containing allantoic fluids. Infectious titers were determined by standard 50% tissue culture infectious dose (TCID₅₀) assay in MDCK cells.

Virus yield reduction assay. Two days prior to infection, MDCK cells were seeded in 96-well plates and the cells were infected with each virus at 100 TCID₅₀/well. The infected cells were incubated at 35°C under 5% CO₂ for 1 hour and wash out the virus inoculum, followed by addition of the fresh medium including 2.5 µg/ml trypsin and defined concentrations of test compounds. BXA and favipiravir were dissolved in dimethyl sulfoxide and NAs were dissolved in distilled water. The cells were incubated at 35°C under 5% CO₂ for 24 hours and virus titers (TCID₅₀/mL) in the culture supernatants were determined in MDCK cells. The 90% effective concentration (EC₉₀) was calculated as the concentration decreasing the virus titers in the culture supernatant to 10% of untreated control values by the linear interpolation method.

Genetic analysis. PA sequences of 10,312 clinical isolates for A(H1N1), 13,185 for A(H3N2), 196 for A(H5N1) and 1,094 for A(H7N9), were downloaded from the National Center for Biotechnology Information (NCBI) and Global Initiative on Sharing All Influenza Data (GISAID) on October 24, 2018. Amino acid sequences of the PA protein were aligned by the ClustalW program in the component of Pipeline Pilot 2018 (BIOVIA), and conservation of amino acid residues in close proximity to the BXA was calculated within individual influenza virus subtypes. The nucleotide sequences were phylogenetically analyzed based on PA genes of H7 avian influenza viruses by the maximum-likelihood method with a Tamura–Nei model and bootstrap analysis (n = 1000) using MEGA 7.0 software with default parameters. Sequence data of PA genes obtained in the present study were compared with those of other reference strains presented in a previous report.

Animal experiments. Experiment 1. Six-week-old female BALB/c mice (Japan SLC, Inc.) were maintained under a controlled temperature environment and humidity. Under anesthesia (1.6 mg/mL zolazepam hydrochloride, 1.6 mg/mL tiletamine hydrochloride and 1.9 mg/mL xylazine hydrochloride in saline), mice were infected intranasally with 50 µL/mouse with 4.0 × 10⁵ TCID₅₀ (low dose, 10.4 of 50% mouse lethal dose [MLD₅₀]) or 1.2 × 10⁶ TCID₅₀ (high dose, 31.1 MLD₅₀) of A/Anhui/1/2013 (H7N9) virus. On the morning of the first day, the first dosing was administered within a few seconds after virus inoculation under anesthesia in the morning of the first day (defined as immediately after virus inoculation). Mice were treated with BXM (0.5 mg/kg/dose [only low dose model], 5 mg/kg/dose, or 50 mg/kg/dose) twice a day (12 hour interval between each dosing) for 1 or 5 day(s) by oral gavage. BXM was suspended with 0.5 w/v% methylcellulose (MC). For the controls, vehicle (0.5 w/v% MC) or oseltamivir phosphate (OSP, 5 mg/kg/dose [clinically-equivalent dose; 75 mg/kg/day]) or 50 mg/kg/dose) was administered twice a day for 5 days by oral gavage. Survival rates and body weight changes were then monitored through a 21 (high dose infection model) or 28-day (low dose infection model) period after the infection (n = 10/group). Virus titers in the lungs of mice at indicated time points were determined in MDCK cells. The viral RNAs derived from lung homogenates of BXM-treated mice was extracted by PureLink Viral RNA/DNA Mini Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Reverse transcription of cDNA and sequencing were performed as previously reported. Primers used in this study were as follows; PA-1F, 5'-ATATCGTCTCGATTAGTAGAACAAAGGTGTTT-3' and PA-955R, 5'-TGCAATTTAGGATCATATAG-3'. Sequence analysis of PA N-terminal domain (the PA gene of A/Anhui/1/2013 [H7N9] strain) was performed by Sanger sequencing method using the 3500/3500XL genetic analyzer (Life Technologies). All animals were housed in self-contained units (Tokiwa Kagaku) at the BSL-3 and ABSL-3 facilities of the Faculty of Veterinary Medicine, Hokkaido University, Japan. Animal experiments were performed according to the guidelines of the institutional animal care and use committee of Hokkaido University (Approval Number 15-0063, 16-0107 and 16-0108). The mice were euthanized when they lost greater than 30% of their body weight compared with their pre-infection weight.

Experiment 2. Under anesthesia, mice were infected intranasally with low dose of A/Anhui/1/2013 (H7N9) virus. Mice were treated with BXM (5 or 50 mg/kg/dose) twice a day for 5 days by oral gavage beginning immediately, 24 or 48 hours after virus inoculation. For the controls, vehicle or OSP (5 mg/kg/dose) was administered twice a day for 5 days by oral gavage beginning immediately after virus inoculation. Dosing volume was 10 mL/
kg calculated by body weight before each dosing. Survival rates and body weight changes were then monitored through a 21-day period after the infection (n = 5/group).

**Quantitative analysis of proinflammatory cytokines and chemokines.** In experiment 1, levels of proinflammatory cytokines and chemokines, including interleukin (IL)-6, monocyte chemotractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α and interferon (IFN)-γ in the lungs, were quantitatively determined using Quantikine ELISA (R&D Systems). The lungs were collected from the virus titer experiments infected with 4.0 × 10^3 TCID_{50} of A/Anhui/1/2013 (H7N9) strain at 1 (only for 1-day treatment group), 3 and 5 dpi. The collected lungs were homogenized, and each sample was processed according to the manufacturer’s protocol.

**Statistical analysis.** For the comparison of the survival time after infection between each BXM-treated group and vehicle-treated or OSP-treated group, the log-rank test was applied in experiment 1 and 2. For the comparison of body weight changes of mice throughout the treatment period, virus titers in the lung tissues or cytokines and chemokines levels in the lung tissues between each BXM-treated group and vehicle-treated or OSP-treated group at each time point were evaluated using Dunnett’s multiple-comparison method in experiment 1. Statistical analysis was performed using the statistical analysis software SAS version 9.2 for Windows (SAS Institute, Cary, NC). P values < 0.05 were considered statistically significant.

**Ethics statement.** All animals were housed in self-contained units (Tokiwa Kagaku) at the BSL-3 and ABSL-3 facilities of the Faculty of Veterinary Medicine, Hokkaido University, Japan. Animal experiments were performed according to the guidelines of the institutional animal care and use committee of Hokkaido University (Approval Number 15-0063, 16-0107 and 16-0108). The mice were euthanized when they lost more than 30% of their body weight compared with their pre-infection weight.

**References**

1. Taubenberger, J. K. & Morens, D. M. Influenza: the once and future pandemic. Public Health Rep. 125, 16–26 (2010).
2. Su, S. et al. Epidemiology, Evolution, and Pathogenesis of H7N9 Influenza Viruses in Five Epidemic Waves since 2013 in China. Trends Microbiol. 25, 713–728 (2017).
3. Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368, 1888–1903 (2017).
4. Zaratek, H. et al. Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck. Nat. Commun. 6, 1–10 (2015).
5. Watanabe, T. et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501, 551–555 (2013).
6. Chan, L. L. Y. et al. Evaluation of the human adaptation of influenza A/H7N9 virus in PB2 protein using human and swine respiratory tract explant cultures. Sci. Rep. 6, 1–11 (2016).
7. de Vries, R. P. et al. Three mutations switch H7N9 influenza to human-type receptor specificity. PLoS Pathog. 13, 1–16 (2017).
8. Guan, Y. et al. Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic - China, October 2016-February 2017. MMWR. Morb. Mortal. Wkly. Rep. 66, 254–255 (2017).
9. Liu, J. et al. H7N9: A low pathogenic avian influenza A virus infecting humans. Curr. Opin. Virol. 5, 91–97 (2014).
10. Zhou, L. et al. Preliminary Epidemiology of Human Infections with Highly Pathogenic Avian Influenza A(H7N9) Virus, China, 2017. Emerg. Infect. Dis. J. 23 (2017).
11. Qi, W. et al. Emergence and adaptation of a novel highly pathogenic H7N9 influenza virus in birds and humans from a 2013–human-infecting low pathogenic ancestor. J. Virol. JVI.00921-17, https://doi.org/10.1128/JVI.00921-17 (2017).
12. Food and Agriculture Organization of the United Nations. H7N9 situation update. Available at: http://www.fao.org/ag/againfo/programmes/en/empires/h7n9/situation_update.html. (Accessed: 3rd October 2018) (2018).
13. Centers for Disease Control and Prevention. Interim Guidance on the Use of Antiviral Medications for Treatment of Human Infections with Novel Influenza A Viruses Associated with Severe Human Disease. Available at, https://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm. (Accessed: 27th July 2018) (2016).
14. Farooqui, A. et al. Assessment of antiviral properties of peramivir against H7N9 avian influenza virus in an experimental mouse model. Antimicrob. Agents Chemother. 59, 7255–7264 (2015).
15. Hu, Y. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381, 2273–2279 (2013).
16. Treanor, J. J. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283, 1016–24 (2000).
17. Lee, N. et al. A prospective intervention study on higherdose oseltamivir treatment in adults hospitalized with influenza A and B infections. Clin. Infect. Dis. 57, 1511–1519 (2013).
18. Kondo, H. et al. Influenza virus shedding in lamimamivir-treated children upon returning to school. Tohoku J. Exp. Med. 238, 113–121 (2016).
19. Zhang, P. et al. Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. J. Infect. 75, 71–75 (2017).
20. Takashita, E. et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 132, 170–177 (2016).
21. de Jong, M. D. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203–1207 (2006).
22. McKimm-Breschkin, J. L. et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72, 2456–62 (1998).
23. Gaymard, A. et al. Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9). J. Antimicrob. Chemother. 71, 3036–3045 (2016).
24. Kageyama, T. et al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill. Bull. Eur. sur les Mal. Transm. = Eur. Commun. Dis. Bull. 18, 20453 (2013).
25. Marukui, H. et al. Characterization of drug-resistant influenza a(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J. Infect. Dis. 211, 249–257 (2015).
26. Dias, A. et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458, 914–918 (2009).
27. Stevaert, A. & Naesens, L. The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design. Med. Res. Rev. 36, 1127–1173 (2016).
28. Stevaert, A. et al. Mutational Analysis of the Binding Pockets of the Diketo Acid Inhibitor L-742,001 in the Influenza Virus PA Endonuclease. J. Virol. 87, 10524–10538 (2013).
29. Tomassini, J. et al. Inhibition of Cap (m7GpppXm) -Dependent Endonuclease of Influenza Virus by 4-Substituted 2, 4-Dioxobutanoic Acid Compounds. Antimicrob. Agents Chemother. 38, 2827–2837 (1994).

30. Jones, J. C. et al. A novel endonuclease inhibitor exhibits broad-spectrum anti-influenza virus activity In Vitro. Antimicrob. Agents Chemother. 60, 5504–5514 (2016).

31. McKimm-Breschkin, J. L. et al. Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral Res. 149, 118–142 (2018).

32. Omoto, S. et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 1–15, https://doi.org/10.1038/s41598-018-27890-4 (2018).

33. Hayden, F. G. et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N. Engl. J. Med. 379, 913–923 (2018).

34. Uehara, T. et al. S-033188, a Small Molecule Inhibitor of Cap-dependent Endonuclease of Influenza A and B Virus, Leads to Rapid and Profound Viral Load Reduction. In OPTIONS IX (2016).

35. Noshi, T. et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res., https://doi.org/10.1016/j.antiviral.2018.10.008 (2018).

36. Yamayoshi, S. et al. Virulence-Affecting Amino Acid Changes in the PA Protein of H7N9 Influenza A Viruses. J. Virol., https://doi.org/10.1128/JVI.03155-13 (2014).

37. Hu, M. et al. Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza Avirus. Sci. Rep., https://doi.org/10.1038/srep37800 (2018).

38. Jones, J. C. et al. Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors. MBio, https://doi.org/10.1128/mBio.00430-18 (2018).

39. Ward, P., Small, L., Smith, J., Suter, P. & Duklewski, R. Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55 (2005).

40. Chi, Y. et al. Cytokine and chemokine levels in patients infected with the novel avian influenza a (H7N9) virus in China. J. Infect. Dis. 208, 1962–1967 (2013).

41. Zhou, J. et al. Biological features of novel avian influenza A (H7N9) virus. Nature 499, 500–3 (2013).

42. Lee, A. C. Y. et al. Avian influenza virus a H7N9 infects multiple mononuclear cell types in peripheral blood and induces dysregulated cytokine responses and apoptosis in infected monocytes. J. Gen. Virol. 98, 922–934 (2017).

43. Wang, X. F. et al. Clinical features of three avian influenza H7N9 virus-infected patients in Shanghai. Clin. Respir. J. 8, 410–416 (2014).

44. Baranovitch, T. et al. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J. Infect. Dis. 209, 1343–1353 (2014).

45. Shihata, A. et al. Repeated detection of H7N9 avian influenza viruses in raw poultry meat illegally brought to Japan by international flight passengers. Virology 524, 10–17 (2018).

46. Zhang, X. et al. Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui lineage) with R292K substitution. Emerg. Microbes Infect., https://doi.org/10.1007/s40261-018-0710-9 (2018).

47. Hay, A. J. & Hayden, F. G. Oseltamivir resistance during treatment of H7N9 influenza infection. The Lancet, https://doi.org/10.1016/S0140-6736(13)61209-X (2013).

48. Hai, R. et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat. Commun., https://doi.org/10.1038/ncomms13854 (2013).

49. Noshi, T. et al. Pharmacokinetic and Pharmacodynamic Analysis of S-033188/S-033447, a Novel Inhibitor of Influenza Virus Cap-dependent Endonuclease, in Mice Infected with Influenza A Virus. In ECCMID 2017. (2017).

50. Fukao, K. et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J. Antimicrob. Chemother. 1–9, https://doi.org/10.1093/jac/dky462 (2018).

51. Koshimichi, H. et al. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clinical Drug Investigation, https://doi.org/10.1007/s40261-018-0710-9 (2018).

52. Tsang, T. K. et al. Individual correlates of infectivity of influenza A virus infections in households. PLoS One 11 (2016).

53. Byrn, R. A. et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59, 1569–1582 (2015).

54. Govorkova, E. A. et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51, 1414–1424 (2007).

55. Bi, Y. et al. A new reassortment of influenza A (H7N9) virus causing human infection in Beijing. 2014. Sci. Rep. 6, 26624 (2016).

56. Wang, Z. et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc. Natl. Acad. Sci. USA 111, 769–774 (2014).

57. Ka, C. et al. Pathogenicity of the Novel A/H7N9 Influenza Virus in Mice. MBio 4, 1–10 (2013).

58. Kobayashi, M. et al. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation. Antiviral Res. 139, 41–48 (2017).

59. Guo, J. et al. The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Sci. Rep. 5, 10942 (2015).

60. Woo, P. C. Y. et al. Cytokine Profiles Induced by the Novel Swine-Origin Influenza A/H1N1 Virus: Implications for Treatment Strategies. Cytokine 201 (2010).

61. Baumgart, N. & Kelso, A. In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J. Virol. 70, 441–4418 (1996).

62. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. A. DNA transfection system for generation of influenza A virus from eight plasmids.pdf, 97, 6108–6113 (2000).

63. Kumar, S., Stecher, G. & Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol. Biol. Evol., https://doi.org/10.1093/molbev/msw654 (2016).

64. Cho, D. H. et al. Potency of an inactivated influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the challenge with A/Anhui/1/2013 (H7N9). Vaccine, https://doi.org/10.1016/j.vaccine.2014.04.009 (2014).

Acknowledgements
We thank Masato Tashiro (National Institute of Infectious Diseases, Japan) for generously providing A/Anhui/1/2013 (H7N9). We thank Animal Quarantine Service, Ministry of Agriculture, Forestry and Fisheries, Japan for generously providing A/duck/Japan/AQ-HE28-3/2016 (H7N9), A/duck/Japan/AQ-HE29-22/2017 (H7N9) and A/duck/Japan/AQ-HE30-1/2018 (H7N3). We thank Naoko Kurihara and Masatomo Rokushima (Shionogi & Co., Ltd., Japan) for bioinformatics analysis. We thank Shinya Omoto (Shionogi & Co., Ltd., Japan) and Michael Carr (GI-CoRE, Hokkaido University, Japan) for critical reading and editing of the manuscript.
Author Contributions
Project design and data analysis by K.T., Y.A., T.N., M. Kobayashi, M. Kawai, R.Y., A.S., T.S. and A.N.; interpretation by K.T., Y.A., T.N., A.S., T.S., A.N., K.M., M.O., Y.S. and H.K.; *in vitro* study by K.T. and T.N.; *in vivo* studies by K.T., Y.A., H.N., S.T. and M. Kobayashi, and manuscript written by K.T. All authors read and approved the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-39683-4.

Competing Interests: The authors K.T., Y.A., H.N., S.T., T.N., M. Kawai., R.Y., A.S., T.S. and A.N. are employees of Shionogi & Co., Ltd. The authors K.M., M.O., Y.S. and H.K. were provided financial support from Shionogi & Co., Ltd. for the studies performed in the manuscript. The author M. Kobayashi. was an employee of Shionogi & Co., Ltd. and now declares no potential conflict of interest. All works reported here were financially supported by Shionogi & Co., Ltd.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019